Scientific Program
Wed
Thu
Fri
Sat
Wednesday, May 7, 2025
Breast Cancer
| Welcome Adress of the Hosts and Greeting Words J.-U. Blohmer and J. Sehouli | |
Presidential Lecture | |
| New Strategies for the Treatment of ER+/HER2-Endocrine-resistant Breast Cancer M. Goetz | |
Live Surgery from 2 operating rooms |
Moderation: M. Karsten, F. Reyal
- Total Breast Reconstruction with AFT
- Conversion from Implant to AFT
- Various Techniques of BCS and SNB
- Gender-affirming Breast Surgery
- Other Breast Surgeries
Surgeons: J.-U. Blohmer, O. Camara,
R. Khouri, A. Piatkowski, C. Neeb,
R. Reinemer, J. K. Wagner, C. Weiler
| Lunch Break | |
Symposium With kind support of Daiichi Sankyo and AstraZenecaSpotlight ADCs: An Update for Breast and Gynaecological CancersChairs: J. Sehouli and J.-U. Blohmer
| |
| Chairs: S. Kümmel and V. Kiver | |
Presidential Lecture | |
| Role of Surgery in Breast Cancer Treatment J.-U. Blohmer | |
Trials | |
| The Most Relevant Clinical Trials (European Perspective, Global Perspective) S. Kümmel | |
Lectures | |
| Invasive Lobular Carcinoma (ILC): Translational Data S. Oesterreich | |
| Invasive Lobular Carcinoma (ILC): Clinical Data M. Karsten | |
| Endocrine Resistance: Translational Data A. Lee | |
| Discussion S. Oesterreich, M. Karsten, A. Lee | |
| Coffee Break | |
| Chairs: J.-U. Blohmer and S. Oesterreich | |
Lectures | |
| The Role of Germline Pathogenic Mutations and Endocrine Sensitivity S. Yadav | |
| Germline Mutations: Digital Tools for Patients and Physicians D. Speiser | |
| TNBC: Identifying New Biomarkers for Treatment Escalation and De-escalation R. Leon Ferre | |
Symposium with kind support of StemlineExtending Endocrine Treatment by Overcoming ESR1 MutationsChair: J.-U. Blohmer
| |
| End of program | |
Please note: On Thursday, there will be more lectures in the parallel session Breast Cancer II.
CMC Crash Course
01:45 to 03:45 pm
Biomarker in Targeted Therapies and Management of Toxicity (ADCs) in Endometrial, Ovarian, and Cervical Cancer
E. I. Braicu, R. Coleman, K. Moore, R. Chekerov, D. Rieke, M. Shahi
CMC Master Course
04:00 to 06:00 pm
Surgical and Topographic Anatomy in Ovarian Cancer and Surgical Complication Management in Gynecological Oncology
J. Sehouli, W. Cliby, C. Fotopoulou, J. Neymeyer
Thursday, May 8, 2025 I/II
Breast Cancer Session II
| Chair: J.-U. Blohmer | |
Hottest Topics in Clinical Routine and ResearchBreast Surgery | |
| Surgical Aspects under TNBC F. Reyal | |
| BCS vs. ME; R0 vs. R1 Resektion C. Weiler | |
| Free Flap or AFT in Breast Reconstruction R. Khouri | |
| Implant or AFT in Breast Reconstruction A. Piatkowski | |
Panel Discussion | |
| Breast Surgery 1 C. Weiler, R. Khouri, A. Piatkowski | |
Breast Surgery and Around | |
| Gender-affirming Surgery R. Reinemer | |
| Risk-reducing Surgery: How to Avoid Pitfalls J.-U. Blohmer | |
| PROs: How to Bring them into Clinical Practice M. Karsten | |
Panel Discussion | |
| Breast Surgery 2 R. Reinemer, J.-U. Blohmer, M. Karsten | |
Video Session | |
| Breast Cancer Surgery | |
| End of this Session / Begin of Lunch Break | |
Parallel to the Session »Redefining Limits« (Gynecologic Oncology)
Thursday, May 8, 2025 II/II
Cervical Cancer, Endometrial Cancer, and other Solid Tumors
Redefining Limits: Interdisciplinary Approaches in Complex Cancer
Surgery in the Management of Gynecological Malignancies
Chairs: J. Sehouli, R. Armbrust, C. L. Langstraat, S. C. Dowdy
Opening Lectures | |
| Principles and Scheduling of Complex Oncological Surgery in an Interdisciplinary and Interprofessional Setting J. Sehouli | |
| Options and Limits of Blood Management for Complex Surgeries L. Kaufner | |
Session 1 | |
| Case Report: Cerebellar Metastasis in an Ovarian Cancer Patient A. Miranda | |
| Brain Metastases – Is there a Role for Surgery in Gynecological Cancer? P. Vajkoczy | |
| Oligometastatic Disease in Ovarian Cancer – Sporadic or Clinically Meaningful? K. Pietzner | |
| Discussion | |
Session 2 | |
| Case Report: Granulosa Cell Tumor Relapse and Major Liver Resection I. Sterner | |
| Beyond Borders: Joint Cases of Hepatobiliary and Gynecological Cancer Surgeons W. Schöning | |
| Discussion | |
| Coffee Break | |
Session 3 | |
| Case Report: Enterovaginal Fistula Incervical Cancer Relapse M. Beck | |
| Radical Pelvic Exenteration – Borders and Limiting Factors A. Kumar | |
| Complex Reconstruction of the Bladder and Ureter J. Neymeyer, M. Z. Muallem | |
| Discussion | |
Session 4 | |
| Case Report: Sarcoma with Bladder and Rectum Infiltration E. Roser | |
| Principles of Sarcoma and Vessel Surgery R. Öllinger | |
| Discussion | |
Session 5 | |
| Case Report: Pleural Effusion and Pleural Carcinomatosis M. Lee | |
| Role of Thoracic Surgery in Lung and Pleural Metastases J. Neudecker | |
| Discussion | |
Session 6 | |
Video Session
| |
| Lunch Break | |
Symposium With kind support of GlaxoSmithKlineNew Treatment Options for First-line Endometrial Cancer – More Complexity and More OpportunitiesChair: J. Sehouli
| |
Cervical CancerChairs: W. Lichtenegger and N. Abu-Rustum | |
Presidential Lecture | |
| Revolution in Cervical Cancer Management, Radical Hysterectomy, Simple Hysterectomy, or Cone Biopsy in Early Stage N. Abu-Rustum | |
Trials | |
| The Most Relevant Clinical Trials (ENGOT, GOG and more) – 10 Minutes Around the World R. Armbrust | |
Hottest Debates in Clinical Routine and ResearchPrimary Local Advanced Cervical Cancer | |
| Neoadjuvant Chemotherapy M. McCormack | |
| Primary Radio-Immuno-Chemotherapy F. Mehrhof | |
| Primary Surgery, When, How, When Not? M. Z. Muallem | |
Panel Discussion | |
| What is the Best Therapy Algorithm? W. Lichtenegger, N. Abu-Rustum, M. McCormack, F. Mehrhof, M. Z. Muallem, B. Monk | |
| Coffee Break | |
Endometrial CancerChairs: K. Pietzner and A. Wahner-Hendrickson | |
Presidential Lecture | |
 Endometrial Cancer Management: Options and Limits to Substitute Chemotherapy?N. Colombo | |
Trials | |
| The Most Relevant Clinical Trials (ENGOT, GOG and More) – 10 Minutes Around the World L. Chinczewski | |
Hottest Debates in Clinical Routine and Research | |
| Primary Chemo-Immunotherapy Plus/Minus PARP Inhibitor M. R. Mirza | |
| What are the Predictive Markers for Response to PARP? E. I. Braicu | |
| What is the Best Medical Therapy in the Relapse Setting (Endocrine, Immuno After Immuno, Chemo after Chemo, PARP after PARP, Role of ADC)? A. Wahner-Hendrickson | |
Panel Discussion | |
| What is the Best Therapy Algorithm? K. Pietzner, M. R. Mirza, E. I. Braicu, A. Wahner-Hendrickson | |
| End of Program | |
CMC Master Course I
01:30 to 03:30 pm
How to Avoid and How to Solve Problems in Breast Surgeries
J.-U. Blohmer, O. Camara, R. Reinemer, S. Paepke, and guests
CMC Master Course II
03:45 to 05:45 pm
Basics of Breast Reconstruction – Implant, Flaps, and AFT
J.-U. Blohmer, O. Camara, R. Reinemer, S. Paepke, and guests
Promoting Innovation in Global Women’s Health through Partnership
UNFPA’s WomenX Collective-Charité-Berlin Institute for Health (BIH)05:30–06:30 pm | Joint Reception (by invitation only)
Chairs:
Dr. Sara Nasser and
Dr. Andreas Ullrich
Promoting Innovation in Global Women’s Health through Partnership
UNFPA’s WomenX Collective-Charité-Berlin Institute for Health (BIH)05:30–06:30 pm | Joint Reception (by invitation only)
Chairs:Dr. Sara Nasser and
Dr. Andreas Ullrich
Friday, May 9, 2025
Ovarian Cancer
| Greeting Words by the FIGO President-Elect F. Louwen | |
Live Surgery from 3 operating rooms |
Moderation: R. Chekerov, S. Dowdy, W. Cliby, M. Renz
- En-bloc Resection
- Peritonectomy
- Nerve-sparing Techniques
- Lymph Node Dissection
- ICG Techniques
- Perioperative Management
Surgeons: J. Sehouli, R. Armbrust, C. Fotopoulou, M.Z. Muallem
★★★
During Live Surgery:
- The Most Challenging Case of the Year
A. Miranda - Scientific Highlight of the Year: Exclusive Charité-Mayo Data
| Lunch Break | |
Symposium With kind support of AbbVieAntibody-Drug Conjugates: Facing Platinum Resistance in Advanced Ovarian Cancer
| |
| Chairs: S. Dowdy and J. Sehouli | |
Presidential Lecture | |
| Primary Surgery or Interval Surgery – What is the Current Evidence? S. Mahner | |
Trials | |
| The Most Relevant Clinical Trials (ENGOT, GOG and more) – 10 Minutes Around the World R. Chekerov | |
Hottest Debates in Clinical Routine and Research | |
| Maintenance Therapy: But what? J. Ledermann | |
| BRCA/HRD-adjusted Surgery in Primary OC? M. Renz | |
| What is the Best Therapy in the HRD Group? B. Monk | |
Panel Discussion | |
| What is the Best Therapy Algorithm? S. Dowdy, J. Sehouli, J. Ledermann, M. Renz, B. Monk | |
| Coffee Break | |
| Chairs: W. Cliby and R. Chekerov | |
Debate | |
Relapsed Ovarian Cancer: Salvage Surgery or Neoadjuvant Therapy?
| |
LecturesPlatinum or Chemo Resistance? Time to Change the Definition and the Treatment Algorithm | |
| ADCs G. Konecny | |
| Rechallenge of Previous Therapy J. Grabowski | |
| Chemotherapy-free Approaches S. Banerjee | |
| Best Supportive Care Only! E. Roser | |
| Palliative Surgery C. Fotopoulou | |
| Discussion | |
| End of Program | |
CMC Master Course
04:30 to 06:30 pm
Prerehabilitation, Fast-track Rehabilitation, ERAS, Minimally Invasive Complication Management
S. Dowdy, A. Kumar, J. Sehouli, M. Lee
Saturday, May 10, 2025
Cross Talk and More
| Chairs: A. Ullrich and S. Nasser | |
Presidential Lecture | |
| How We Can Improve Women’s Health D. Sood  | |
Lectures | |
| Screening for Cardiovascular Diseases in Women U. Landmesser | |
| Biomarker in Targeted Therapies: Yesterday, Today, Tomorrow K. Moore | |
| How to Translate Guidelines into Regions with Limited Resources D. Cibula | |
| Chairs: D. Cibula and J.-U. Blohmer, P. Wimberger | |
Learning Across the Diseases | |
| Endocrine Therapy: What is the Code in Breast Cancer, What in Gynecological Malignancies? | |
| |
| |
| |
| PARP Inhibitors: What is the Code in Gynecologcial Malignancies, What in Breast Cancer, What in Other Solid Tumors and Who are the Best Candidates? | |
| |
| |
| |
| Checkpoint Therapy: What is the Code in Gynecologcial Malignancies, What in Breast Cancer, What in Other Solid Tumors? | |
| |
| |
| |
Lunch Break During Lunch Break: | |
| ADCs: What is the Code in Gynecologcial Malignancies, What in Breast Cancer, What in Other Solid Tumors? | |
| |
| |
| |
Lectures | |
| Leveraging AI to Decode and Replicate Cellular Architecture: A Vision for the Future S. Quake | |
| AI Biomarkers for Precision Oncology J. N. Kather | |
New Options in the Management of Malignant Ascites
| |
Closing Session | |
| 3 Best Posters: Discussion and Acknowledgment Poster Awards | |
| Closing Words and Farewell J.-U. Blohmer and J. Sehouli | |
| End of Program | |
CMC Cadaver Course
08:00 to 12:00 pm
Gynecology
M. Z. Muallem, A. Miranda, T. Jöns, O. Camara
Status: 03/2025; May be subject to change.